Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature. by van der Hilst, Jeroen Ch et al.
© 2016 van der Hilst et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/
terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the 
work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For 
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Biologics: Targets and Therapy 2016:10 75–80
Biologics: Targets and Therapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
75
O r i g i n a l  r e s e a r c h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/BTT.S102954
Efficacy of anti-IL-1 treatment in familial 
Mediterranean fever: a systematic review of the 
literature





1Department of infectious diseases 
and immunity, Jessa hospital, 
hasselt, 2Biomedical research 
institute, University of hasselt, 
hasselt, 3Department of immunity 
and infectious Diseases, University 
hospital of liège, liège, 4service 
de rhumatologie, cliniques 
Universitaires Saint-Luc, 5institut de 
recherche expérimentale et clinique, 
Université catholique de louvain, 
Brussels, 6KU leuven, laboratory of 
clinical infectious and inflammatory 
Disorders, University hospitals 
leuven, leuven, Belgium
correspondence: Jeroen ch van der hilst 
Department of infectious Diseases and 
immunity, Jessa hospital, stadsomvaart 11, 
3500 hasselt, Belgium 
Tel +32 11 309 485 
Fax +32 11 309 488 
email jeroen.vanderhilst@jessazh.be
Introduction: In 5%–10% of patients with familial Mediterranean fever (FMF), colchicine 
is not effective in preventing inflammatory attacks. Another 5%–10% of patients are intoler-
ant to effective doses of colchicine and experience serious side effects. Treatment with anti-
interleukin-1 (IL-1) drugs may be an alternative for these patients, although it is not reimbursed 
for this indication in many countries.
Methods: We systematically searched PubMed, Web of Science, and Scopus for reports of 
anti-IL-1 treatment in FMF patients.
Results: Out of 284 potentially relevant articles, 27 eligible reports were identified and included 
in the data analysis.
Conclusion: A complete response to therapy without a single attack during treatment was 
reported in 76.5% of patients on anakinra treatment and in 67.5% of patients during canaki-
numab treatment. In patients with established type AA amyloidosis, anti-IL-1 treatment can 
reverse proteinuria. Anti-IL-1 therapy seems to be a safe and effective alternative for patients 
with FMF who do not respond to or cannot tolerate colchicine.
Keywords: familial Mediterranean fever, interleukin-1, amyloidosis, colchicine
Introduction
Familial Mediterranean fever (FMF) is an autosomal recessive disease characterized by 
recurrent attacks of fever. Fevers typically last 12 hours–3 days and are accompanied 
by serositis, such as peritonitis, pleuritis, pericarditis, and arthritis.1 There is a subgroup 
of patients, mostly with a M694V homozygous genotype, who have a more severe 
phenotype and also suffer from inflammation in between attacks.2 Colchicine has been 
shown to be effective in controlling inflammation in the majority of patients. However, 
an estimated 5%–10% of patients do not respond to colchicine.3 Furthermore, another 
5%–10% of patients are intolerant to effective doses of colchicine and experience serious 
side effects, including severe diarrhea, neuropathy, rhabdomyolysis, and bone marrow 
suppression.4 For these patients, a therapeutic alternative for colchicine is needed.
In recent years, it has been shown that interleukin-1 (IL-1) plays a central role in the 
pathogenesis of inflammation in most autoinflammatory diseases.5 Inhibiting the action 
of IL-1 is therefore a logical step in controlling inflammation in these autoinflamma-
tory diseases. Indeed, IL-1 blocking drugs have been proven successful in inhibiting 
inflammation in several autoinflammatory diseases, including cryopyrin-associated 
periodic syndrome,6,7 tumor necrosis factor receptor-associated periodic syndrome,8,9 
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Currently, three anti-IL-1 drugs are available.12 Anakinra is 
a recombinant homolog of the human IL-1 receptor that com-
petitively inhibits binding of IL-1-alpha and -beta to its receptor. 
It is administered as a daily subcutaneous injection. Canaki-
numab is a human IgG antibody directed against IL-1-beta. It 
is administered subcutaneously every 4–8 weeks. Rilonacept is 
a dimeric fusion protein consisting of the extracellular portions 
of the human IL-1 receptor and the Fc region of human IgG1 
that binds and neutralizes IL-1. Although adding anti-IL-1 
treatment seems promising when colchicine causes serious side 
effects or is ineffective, there is currently no reimbursement in 
Belgium for FMF patients. Recently, the Belgian Network for 
Auto-Inflammatory Diseases was founded (www.bnaid.be). 
The Belgian Network for Auto-Inflammatory Diseases consists 
of a network of physicians who have expertise in diagnosing 
and treating patients with autoinflammatory diseases. In order 
to make a statement on the optimal treatment of patients with 
colchicine-resistant FMF and FMF patients with serious side 
effects of colchicine, we performed a systematic review of the 
literature that aimed to summarize all available evidence of 
anti-IL-1 therapies in patients with FMF.
Methods
We followed a protocol using the methodological 
approaches outlined in the Agency for Healthcare Research 
and Quality’s Methods Guide for Effectiveness and Com-
parative Effectiveness Reviews and applied the Preferred 
Reporting Items for Systematic Reviews and Meta-
Analyses guidelines.13 The systematic literature review 
aimed to include all studies published until October 1, 
2015, reporting on anti-IL-1 therapy in FMF patients. We 
searched Medline, Web of Science, and Scopus using the 
following syntax: (anakinra OR anti-IL-1 OR canakinumab 
OR Rilonacept) AND (familial Mediterranean fever OR 
FMF) in all fields.
study selection
The selection was performed by one investigator (JH). 
We included randomized controlled trials, nonrandom-
ized trials, retrospective analysis of these trials, cohort 
studies or cross-sectional studies, case reports, and case 
series. There were no language restrictions. We excluded 
in vitro and animal studies, review articles, and congress 
abstracts. We assessed all titles and abstracts identified 
by our search. Publications were considered eligible for 
the analysis if they contained data on any of the anti-IL-1 
therapies in patients with FMF as defined by the Tel 
Hashomer criteria.14 Full-length articles were retrieved 






































Records identified through 
Web of Science
(n=140)
Figure 1 selection of literature.
Note: Databases were last consulted on October 15, 2015.
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chae et al20 1 1 1 1 0/1 1 6
Belkhir et al33 1 0 1 1 1/1 1 5
gattringer et al22 2 0 2 0 2/0 2 4.5
Kuijk et al21 1 0 0 0 1/0 1 9
calligaris et al32 1 0 0 0 1/0 0 15
Mitroulis et al23 1 1 1 0 1/0 1 6
roldan et al25 1 1 0 0 1/0 1 6
Moser et al24 1 1 1 1 1/0 1 20
Petropoulou et al27 1 1 1 0 1/0 1 4
Meinzer et al41 6 4 0 0 5/1 5 73
Özen et al28 3 2 0 0 3/0 1 48
alpay et al26 1 1 1 1 0/1 1 2
hennig et al18 1 1 1 1 1/0 1 nr
Stankovic Stojanovic et al30 4 1 4 4 4/0 4 56
estublier et al29 1 1 1 0 1/0 1 12
soriano et al19 1 1 1 0 0/1 1 17
celebi et al31 1 0 1 1 1/0 1 8
Mercan et al34 2 0 2 0 2/1 2 3
Özçakar et al39 10 4 3 6 10/1 8 179
cetin et al40 12 7 10 1 12/1 7 198
eroglu et al38 11 nr nr 1 11/1 7 172
sevillano et al35 1 1 1 1 1/1 1 42
Abbreviations: IL-1, interleukin-1; NR, not reported.
Data extraction
Using a standardized data extraction sheet, the following 
data were collected from the articles: lead author, publica-
tion year, study design, sample size, reason for anti-IL-1 
use, MEFV-mutation, presence of type AA amyloidosis, the 
response to therapy, and follow-up since the start of anti-IL-1 
treatment. In addition, the following baseline characteristics 
were extracted: age of the patients and the number and pro-
portion of male patients. Patients were considered to have a 
complete response if there was not a single attack while on 
anti-IL-1 medication.
Results
The literature search yielded 27 studies that reported on 
the effect of anti-IL-1 treatment in FMF patients. Twenty-
four were case reports or case series, two were open-label 
prospective trials,15,16 and one was a placebo-controlled 
prospective trial.17
Eighteen reports contained data on treatment with 
anakinra,18–35 four on treatment with canakinumab,15,16,36,37 
and four on patients treated with either anakinra or 
canakinumab.38–41 In addition, there is one study that reports 
on the use of rilonacept.17
Effects of anakinra
Since 2006, there have been 22 publications reporting on the 
effect of anakinra that included 64 patients from ten different 
countries. The data are presented in Table 1. The cumulative 
follow-up was 885 months. A complete response during 
treatment was reported in 76.5% of patients. An additional 
18.8% of patients had a decrease in attack frequency and 
inflammation. Only in three patients, there was no clinical 
response to anakinra. Two of the three patients switched 
to canakinumab with favorable clinical response. Data on 
MEFV genotype were available for 51 patients; 72.5% were 
homozygote for M694V mutation.
Nineteen of the 64 patients who were treated with 
anakinra already had type AA amyloidosis at the start of 
treatment. Four patients had nephrotic syndrome.35,38–40 In 
all four patients, a decrease in proteinuria was observed 
after initiation of anakinra. In five patients, anakinra was 
started after patients received a renal transplantation, with 
no recurrences of AA amyloidosis in the kidney transplant 
reported. Eight patients had end-stage renal disease when 
anakinra was started. Three of these patients underwent renal 
transplantation while on anakinra treatment. No recurrence 
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Effects of canakinumab
Eight studies including 40 patients reported on the treatment 
of canakinumab in FMF (Table 2). The cumulative follow-
up period was 427 months. In 67.5% of patients, a complete 
response was reported. In the remaining 32.5%, a partial 
response with reduced attack frequency and inflammation 
was noticed. There were no reports of treatment failure of 
canakinumab. One patient treated with canakinumab had 
type AA amyloidosis. A significant decrease in urinary 
protein excretion after canakinumab (25.6–12 mg/m2/h) 
was recorded.42 Data on MEFV genotype were available for 
31 patients; 77.4% were homozygote for M694V mutation. 
Seven patients had used anakinra before they started with 
canakinumab. In four patients, anakinra was stopped because 
of side effects. None of these patients had reported side 
effects while on canakinumab. In two patients, anakinra was 
unsuccessful in controlling inflammation. In both patients, 
canakinumab resulted in a complete response.
effects of rilonacept
The effect of rilonacept has been studied in a randomized, 
double blind, placebo-controlled trial including 14 patients. 
A complete remission during the 3-month rilonacept course 
was reported in two patients. Eight patients had a partial 
response, while in four patients, there was no significant 
reduction in attack frequency.
Safety of anti-IL-1 treatment
Serious side-effects warranting the discontinuation of 
anakinra were reported in five patients. This included four 
patients with injection site reactions, one patient with injec-
tion site reactions, and one patient who developed inter-
stitial pneumonia possibly related to anakinra use. There 
were no adverse events reported requiring the cessation of 
canakinumab or rilonacept. Notably, there were no cases of 
neutropenia or serious infections necessitating the discon-
tinuation reported.
Discussion
The current systematic review indicates that anti-IL-1 treat-
ment is effective for patients with colchicine-resistant FMF 
and for patients who are unable to tolerate colchicine. All 
three currently available anti-IL-1 drugs were effective in 
suppressing inflammatory attacks. In the majority of patients, 
a complete remission with absence of even a single attack 
was reported.
Because FMF severely affects quality of life, prevention 
of attacks is important.43 In addition, the ability to control 
inflammation is directly related to the risk of type AA amy-
loidosis.44,45 If inflammation cannot be controlled, type AA 
amyloidosis develops in up to three-quarter of patients dur-
ing life.46 It is therefore essential to suppress inflammation 
in order to prevent this severe complication. In patients with 
already established nephrotic syndrome caused by type AA 
amyloidosis, a significant reduction in proteinuria was 
consistently observed. Furthermore, in patients with renal 
transplantation, no recurrences of amyloidosis were seen 
when patients were on anti-IL-1 treatment.
The optimal treatment of colchicine-resistant FMF 
remains unclear and largely based on low-quality evidence. 
The current literature does not allow to make a statement 
about optimal dosing. The lack of high-quality evidence also 
precludes judgment about superiority of one of the anti-IL-1 
treatments over another. In addition, since most reports in 
our review are case reports or case series, there is a potential 
risk of publication bias.
However, despite the fact that colchicine resistance and 
colchicine toxicity in FMF are rare complications of a rare 
disease, results of 27 publications representing .100 patient-
years of follow-up are available. The results of anti-IL-1 
Table 2 Effect of canakinumab




















Meinzer et al41 2 1 0 0 2/0 2 9
Mitroulis et al37 1 0 1 0 1/0 1 24
Brik et al15 7 5 0 0 7/0 3 42
Özçakar et al39 3 0 2 0 3/0 0 56
alpa and roccatello36 1 0 1 0 1/0 0 24
cetin et al40 8 4 6 0 8/0 6 137
eroglu et al38 9 nr nr 1 9/0 7 108
gül et al16 9 7 nr 0 9/0 8 27
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treatment are remarkably consistent and show a dramatic 
clinical response with a favorable safety profile in the major-
ity of patients with a hitherto very difficult to treat condition 
without therapeutic alternatives.
Prospective placebo-controlled trials are currently being 
performed both for anakinra47 and canakinumab (Clinical-
Trials.gov identifier: NCT02059291). 
Conclusion
Based on the results of the current review, anti-IL-1 therapy 
seems to be a safe and effective alternative for patients with 
FMF who do not respond to or cannot tolerate colchicine.
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